239 related articles for article (PubMed ID: 35433955)
21. FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer.
Ay S; Atcı MM; Arıkan R; Dülgar Ö; Özyükseler DT; Paksoy N; Doğan İ; Öztosun B; Taştekin D; Öven BB; Gümüş M
J Chemother; 2022 Nov; 34(7):465-471. PubMed ID: 35037592
[TBL] [Abstract][Full Text] [Related]
22. Treatment Outcomes and Prognostic Factors of Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy after Modified FOLFIRINOX in Unresectable Pancreatic Cancer.
Mie T; Sasaki T; Takeda T; Okamoto T; Hamada T; Ishitsuka T; Yamada M; Nakagawa H; Furukawa T; Kasuga A; Matsuyama M; Ozaka M; Sasahira N
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672308
[TBL] [Abstract][Full Text] [Related]
23. Study of Gemcitabine Plus Nab-Paclitaxel-Based Chemotherapy Regimen as First-Line Treatment in Metastatic Pancreatic Carcinoma.
Domadia K; Goel V; Koyyala VPB; Patnaik N; Chaudhari K; Raina S; Doval DC; Talwar V
South Asian J Cancer; 2022 Jan; 11(1):31-35. PubMed ID: 35833047
[TBL] [Abstract][Full Text] [Related]
24. PD-1 blockade combined with gemcitabine plus nab-paclitaxel is superior to chemotherapy alone in the management of unresectable stage III/IV pancreatic cancer: a retrospective real-world study.
Cheng D; Hu J; Wu X; Wang B; Chen R; Zhao W; Fang C; Ji M
Front Oncol; 2023; 13():1281545. PubMed ID: 37965469
[TBL] [Abstract][Full Text] [Related]
25. Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial.
Bekaii-Saab T; Okusaka T; Goldstein D; Oh DY; Ueno M; Ioka T; Fang W; Anderson EC; Noel MS; Reni M; Choi HJ; Goldberg JS; Oh SC; Li CP; Tabernero J; Li J; Foos E; Oh C; Van Cutsem E
EClinicalMedicine; 2023 Apr; 58():101897. PubMed ID: 36969338
[TBL] [Abstract][Full Text] [Related]
26. A real-world study of anlotinib combined with GS regimen as first-line treatment for advanced pancreatic cancer.
Zhan G; Hu J; Da S; Weng J; Zhou C; Wen F; Liu S; Fang F; Shen E; Zhou Q; Luo P; Xu M; Zhan D; Su Y
Front Endocrinol (Lausanne); 2023; 14():1110624. PubMed ID: 36742383
[TBL] [Abstract][Full Text] [Related]
27. Comparative effectiveness and resource utilization of
Braiteh F; Patel MB; Parisi M; Ni Q; Park S; Faria C
Cancer Manag Res; 2017; 9():141-148. PubMed ID: 28461766
[TBL] [Abstract][Full Text] [Related]
28. Prolonged progression-free survival achieved by gemcitabine, cisplatin, and albumin-bound paclitaxel for the treatment of advanced biliary tract cancers.
Choi JH; Park H; Park JK; Lee JK; Lee KT; Lee KH
Ther Adv Med Oncol; 2024; 16():17588359231225045. PubMed ID: 38249335
[TBL] [Abstract][Full Text] [Related]
29. Early detection of venous thromboembolism after the initiation of chemotherapy predicts a poor prognosis in patients with unresectable metastatic pancreatic cancer who underwent first-line chemotherapy with gemcitabine plus nab-paclitaxel.
Yamai T; Ikezawa K; Hiraga E; Kawamoto Y; Hirao T; Higashi S; Daiku K; Maeda S; Abe Y; Urabe M; Kai Y; Takada R; Nakabori T; Fukutake N; Uehara H; Fujita M; Ohkawa K
PLoS One; 2022; 17(3):e0264653. PubMed ID: 35231078
[TBL] [Abstract][Full Text] [Related]
30. Attenuated regimen of biweekly gemcitabine/nab-paclitaxel in patients aged 65 years or older with advanced pancreatic cancer.
Rehman H; Chi J; Hakim N; Goyal SP; Olazagasti C; Jose J; Moriarty L; Saif MW
Therap Adv Gastroenterol; 2020; 13():1756284820974912. PubMed ID: 33281939
[TBL] [Abstract][Full Text] [Related]
31. Adjuvant nab-paclitaxel plus gemcitabine
Yin ZZ; Zhao ZM; Tang WB; Jiang N; Zhang KD; Song YY; Wang Y; Li CG; Gao YX; Liu R
World J Clin Cases; 2020 Jul; 8(13):2778-2786. PubMed ID: 32742988
[TBL] [Abstract][Full Text] [Related]
32. Treatment outcomes of erlotinib plus gemcitabine as late-line chemotherapy in unresectable pancreatic cancer.
Mie T; Sasaki T; Takeda T; Okamoto T; Mori C; Furukawa T; Yamada Y; Kasuga A; Matsuyama M; Ozaka M; Sasahira N
Jpn J Clin Oncol; 2021 Aug; 51(9):1416-1422. PubMed ID: 34128055
[TBL] [Abstract][Full Text] [Related]
33. Real-world efficacy and safety of nab-paclitaxel plus gemcitabine-cisplatin in patients with advanced biliary tract cancers: a multicenter retrospective analysis.
Cheon J; Lee CK; Sang YB; Choi HJ; Kim MH; Ji JH; Ko KH; Kwon CI; Kim DJ; Choi SH; Kim C; Kang B; Chon HJ
Ther Adv Med Oncol; 2021; 13():17588359211035983. PubMed ID: 34394748
[TBL] [Abstract][Full Text] [Related]
34. Safety and Efficacy Analysis of PD-1 Inhibitors in Combination with Gemcitabine Plus Nab-Paclitaxel for Advanced Pancreatic Cancer: A Real-World, Single-Center Study.
Chen Z; He Y; Ding C; Chen J; Gu Y; Xiao M; Li Q
Onco Targets Ther; 2023; 16():923-935. PubMed ID: 37965584
[TBL] [Abstract][Full Text] [Related]
35. Impact of Nab-Paclitaxel-based Second-line Chemotherapy in Metastatic Pancreatic Cancer.
Dadi N; Stanley M; Shahda S; O'Neil BH; Sehdev A
Anticancer Res; 2017 Oct; 37(10):5533-5539. PubMed ID: 28982867
[TBL] [Abstract][Full Text] [Related]
36.
Tabernero J; Kunzmann V; Scheithauer W; Reni M; Shiansong Li J; Ferrara S; Djazouli K
Onco Targets Ther; 2017; 10():591-596. PubMed ID: 28203092
[TBL] [Abstract][Full Text] [Related]
37. Gemcitabine plus Nab-paclitaxel as a second-line treatment following FOLFIRINOX failure in advanced pancreatic cancer: a multicenter, single-arm, open-label, phase 2 trial.
Huh G; Lee HS; Choi JH; Lee SH; Paik WH; Ryu JK; Kim YT; Bang S; Lee ES
Ther Adv Med Oncol; 2021; 13():17588359211056179. PubMed ID: 34790261
[TBL] [Abstract][Full Text] [Related]
38. Comparative effectiveness and safety of
Mudad R; Patel MB; Margunato-Debay S; Garofalo D; Lal LS
Lung Cancer (Auckl); 2017; 8():179-190. PubMed ID: 29089791
[TBL] [Abstract][Full Text] [Related]
39. Gemcitabine Plus Anlotinib Is Effective and Safe Compared to Gemcitabine Plus Docetaxel in Advanced Soft Tissue Sarcoma.
Liu Z; Wang X; Wang J; Zhang P; Li C; Wang B; Liu G; Yao W
Front Oncol; 2022; 12():922127. PubMed ID: 35912272
[TBL] [Abstract][Full Text] [Related]
40. The Efficacy and Safety of PD-1 Inhibitors Combined with Nab-Paclitaxel Plus Gemcitabine versus Nab-Paclitaxel Plus Gemcitabine in the First-Line Treatment of Advanced Pancreatic Cancer: A Retrospective Monocentric Study.
Zhang F; Wang Y; Yang F; Zhang Y; Jiang M; Zhang X
Cancer Manag Res; 2022; 14():535-546. PubMed ID: 35173487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
